Our present study evaluates the ability of aCD40 to improve anti-tumor immunity via DC activation and subsequent T cell priming and activation and to synergize with checkpoint blockade in a syngeneic mouse model of ER + breast cancer. This evidence concerns the gene ESR1 and breast cancer.